Changran Wei
Impact in
-
- Hippo pathway signaling and YAP/TAZ
-
- Cancer-related Molecular Pathways
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Hippo pathway signaling and YAP/TAZ 4
- Oncology 3
- Cancer Immunotherapy and Biomarkers 2
- Co-authors
- Xiangqi Li (9 shared papers)Ying Wang (1 shared paper)Jiesi Luo (1 shared paper)Yue Li (1 shared paper)Xiangqi Li (1 shared paper)Meng Zhang (1 shared paper)
- Journals
- International Immunopharmacology (2 papers)OncoTargets and Therapy (1 paper)Frontiers in Oncology (1 paper)Frontiers in Pharmacology (1 paper)BMC Cancer (1 paper)
- Partner nations
- China
In The Last Decade
Changran Wei
11 papers receiving 308 citations
Peers
Comparison fields: 5 of 53
- Cell Biology 108
- Oncology 64
- Cancer Research 34
- Molecular Biology 140
- Immunology 33
Countries citing papers authored by Changran Wei
This map shows the geographic impact of Changran Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changran Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changran Wei more than expected).
Fields of papers citing papers by Changran Wei
This network shows the impact of papers produced by Changran Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changran Wei. The network helps show where Changran Wei may publish in the future.
Co-authors
The 7 scholars most cited alongside Changran Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 74 | |
| 2 | 2018 | 67 | |
| 3 | 2020 | 43 | |
| 4 | 2022 | 39 | |
| 5 | 2021 | 36 | |
| 6 | 2022 | 26 | |
| 7 | 2020 | 8 | |
| 8 | 2020 | 6 | |
| 9 | 2022 | 5 | |
| 10 | 2021 | 5 | |
| 11 | The role and correlation analysis of PI3K/AKT pathway in breastcarcinoma with lymph node metastasis | 2018 | 1 |
About Changran Wei
Changran Wei is a scholar working on Cell Biology, Oncology, Immunology, Molecular Biology and Paleontology, having authored 11 papers that have together received 310 indexed citations. Recurring topics across this work include Hippo pathway signaling and YAP/TAZ (4 papers), Wnt/β-catenin signaling in development and cancer (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Immunotherapy and Immune Responses (1 paper), Microbial Community Ecology and Physiology (1 paper), Probiotics and Fermented Foods (1 paper), Circular RNAs in diseases (1 paper) and Psoriasis: Treatment and Pathogenesis (1 paper). The work is most often cited by research in Cell Biology (108 citations), Oncology (64 citations), Cancer Research (34 citations), Molecular Biology (140 citations) and Immunology (33 citations). Changran Wei has collaborated with scholars based in China. Frequent co-authors include Xiangqi Li, Ying Wang, Jiesi Luo, Yue Li, Xiangqi Li, Meng Zhang and Ying Wang. Their work appears in journals such as International Immunopharmacology, OncoTargets and Therapy, Frontiers in Oncology, Frontiers in Pharmacology and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.